Ignyta's Entrectinib Data Sets Prospects Alight

 
• By Alexandra Shimmings

Interim data from STARTRK-2 study point to best-in-class status for Ignyta's entrectinib in a subset of non-small cell lung cancer patients – posing a threat to Xalkori. US NDA filings are set for 2018.

Star exploding
STARTRK data ignite etrectinib's prospects • Source: Shutterstock

More from Clinical Trials

More from R&D